FourKites Signs on as Collaborator to Consortium of Supply Chain Leaders Working to Streamline Scheduling Technology Across the Logistics Industry
Leading real-time supply chain visibility provider FourKites® today announced its role as a Collaborator in the Scheduling Standards Consortium (SSC) as the first real-time visibility platform participating. FourKites joins organisations involved with the SSC — including Arrive Logistics, BlueYonder, Coyote Logistics, DHL, e2open, Echo, J.B. Hunt Transport, Lineage, Mastery, One Network Enterprises, Oracle, Ryder, TI NTG, Uber Freight, Werner and Worldwide Express — which aims to foster greater efficiency within the supply chain technology landscape.
Freight scheduling has been a pervasive problem for the supply chain, compounded by the past decade’s tremendous growth and diversification in scheduling solutions. Shippers and carriers today are responsible for juggling dozens of methods of scheduling freight with shippers, each with their own interface and API, which creates friction and inefficiencies throughout the supply chain.
In response to this challenge, J.B. Hunt and Uber Freight joined forces in 2022 to establish the SSC, to create the first universal appointment scheduling standard in the form of an API. With many leading organisations now involved and driving the Standard forward, the SSC’s goal is to simplify the integration of systems across the fragmented ecosystem between shippers, carriers and intermediaries to create a more efficient appointment scheduling process. The SSC has endorsed a universal standard for the API, released October 2, 2023, which eliminates the need for multiple interfaces and allows carriers to interact through a single interface.
“Embracing a universal scheduling API unlocks seamless coordination across supply chains,” explains Viral Parekh, Head of Logistics Operations at The Kraft Heinz Company. “As more companies endorse this unified approach, we pave the way for unparalleled system efficiency, streamlining operations and driving transformative growth throughout the industry.”
FourKites is collaborating with the SSC because of its proven commitment to optimising ecosystem performance, carrier success and building a more user-friendly operating environment. In addition, FourKites’ robust customer base and recognised industry leadership enables it to play a role in developing the API and accelerating adoption across its customer and partner network. With over 100,000 appointments scheduled in the platform every month, Slot Manager is one of FourKites’ fastest-growing products, as it significantly eliminates the friction associated with manual time slot booking.
“We’re thrilled to participate in this consortium of industry heavy-hitters,” said Mathew Elenjickal, founder and CEO of FourKites. “A single API between our Slot Manager solution and our shippers’ carrier networks will create a frictionless operating environment for everyone involved, and will make FourKites customers Shippers of Choice, with lower cost to serve and a reliable, reputable integration.”
The SSC’s main objectives are to define the API standard for sharing scheduling information, eliminate manual processes by automating interactions where possible, implement standardised interfaces and integrations across core platforms, and advocate the standard across the industry.
About the Scheduling Standards Consortium (SSC)
Founded in 2022 by Convoy, J.B. Hunt and Uber Freight, the Scheduling Standards Consortium (SSC) was established to create freight appointment scheduling standards that provide consistent visibility into the supply chain. Together with shippers, carriers and intermediaries, the SSC aims to simplify the integration of systems across the fragmented ecosystem and generate efficiency across the freight industry. To learn more, visit www.FreightAPIs.org.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,500 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529642423/en/
Contact information
Media:
Scott Johnston
European PR Director, FourKites
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
